Tumours of the Immune System

Abstract

Tumours of the immune system are malignant proliferations of haematopoietic cells, and are classified according to their cell of origin. Disorders of the myeloid lineage result in acute or chronic myeloid malignancy, whereas disorders of the lymphoid lineage result in Hodgkin lymphoma, non‐Hodgkin lymphoma (NHL) and multiple myeloma. These malignancies share many similarities in that acquired genetic changes are involved in their aetiology and are useful prognostic markers. The diagnosis of these conditions involves microscopic examination of peripheral blood or tumour biopsy and often, bone marrow examination. This is also supplemented by immunophenotyping and cytogenetic and molecular analysis. Treatment has previously been based on nonspecific cytotoxic agents and external beam irradiation but increasingly, targeted therapies such as the tyrosine kinase inhibitor, imatinib, and monoclonal antibodies are included in frontline therapy.

Key Concepts:

  • Tumours of the immune system are classified based on morphologic, cytochemical, immunophenotypic, and genetic features.

  • These malignancies exhibit a range of behaviour, with some developing extremely slowly over years, requiring minimal or no therapy, whereas others are among the most aggressive malignancies known and require treatment as emergencies.

  • Most types present most often in the elderly, but they occur throughout life and some are among the commonest childhood malignancies.

  • Cytogenetic and molecular abnormalities are invaluable in guiding the diagnosis and management route of some haematological malignancies.

  • General treatment options comprise radiotherapy, chemotherapy and targeted therapies, depending on the specific disease.

  • A proportion of these malignancies are curable with appropriate treatment, whereas others are susceptible to long term control which falls short of complete eradication, and may require multiple episodes of treatment.

  • This is a field in which research into mechanisms of pathogenesis and therapy is having a direct impact upon treatments and cures.

Keywords: leukaemia; lymphoma; myeloma; chemotherapy; immunotherapy; stem cell transplantation

References

Baccarani M, Cortes J, Pane F et al. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of Europena LeukemiaNet. Journal of Clinical Oncology 27: 6401–6451.

Druker BJ, Guilhot F, O'Brien SG et al. (2006) Five‐year follow‐up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine 355: 2408–2417.

Fenaux P, Le Deley MC, Castaigne S et al. (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukaemia: results of a multicenter randomised trial. Blood 82: 3241–3249.

Goldstone AH, Richards SM, Lazarus HM et al. (2008) In adults with standard‐risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111: 1827–1833.

Grimwade D, Hills RK, Moorman AV et al. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116: 354–365.

Grimwade D, Walker H, Oliver F et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood 92: 2322–2333.

Hallek M, Fischer K, Fingerle‐Rowson G et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open‐label, phase 3 trial. Lancet 376: 1164–1174.

Hamblin TJ, Davis Z, Gardiner A, Oscier DG and Stevenson FK (1999) Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood 94: 1848–1854.

Hasenclever D, Diehl V, Armitage JO et al. (1998) A prognostic score for advanced Hodgkin's disease. New England Journal of Medicine 339: 1506–1514.

Jankovic M, Brouwers P, Valsecchi MG et al. (1994) Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. Lancet 344: 224–227.

Johnson PW, Sydes MR, Hancock BW et al. (2010) Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial. Journal of Clinical Oncology 28: 3352–3359.

Kolb HJ, Shattenberg A, Goldman JM et al. (1995) Graft‐versus‐leukaemia effect of donor lymphocyte transfusions in marrow engrafted patients. Blood 86: 2041–2050.

Linch DC, Winfield D, Goldstone AH et al. (1993) Dose intensification with autologous bone‐marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomised trial. Lancet 341: 1051–1054.

Marcus R, Imrie K, Solal‐Celigny P et al. (2008) Phase III study of R‐CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology 26: 4579–4586.

Wotherspoon AC, Doglioni C, Diss TC et al. (1993) Regression of primary low‐grade B‐cell gastric lymphoma of mucosa‐associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–577.

Further Reading

Hoffbrand AV (2010) Postgraduate Haematology. Chichester: Wiley‐Blackwell.

Swerdlow SH, Campo E, Harris NL et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer.

Web Links

Cancer Research UK http://cancerhelp.cancerresearchuk.org/type/lymphoma/

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Johnson, Peter WM, and Lim, Sean H(May 2012) Tumours of the Immune System. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0001248.pub2]